Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2

The severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) has resulted in almost 28 million cases of COVID-19 (Corona virus disease-2019) and more than 900000 deaths worldwide since December 2019. In the absence of effective antiviral therapy and vaccine, treatment of COVID-19 is largely sym...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaur, Upinder, Acharya, Kumudini, Mondal, Ritwick, Singh, Amit, Saso, Luciano, Chakrabarti, Sasanka, Chakrabarti, Sankha Shubhra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485553/
https://www.ncbi.nlm.nih.gov/pubmed/32926917
http://dx.doi.org/10.1016/j.ejphar.2020.173545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485553/
https://www.ncbi.nlm.nih.gov/pubmed/32926917
http://dx.doi.org/10.1016/j.ejphar.2020.173545

Ejemplares similares